Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Express Scripts
Boehringer Ingelheim
Johnson and Johnson
Baxter

Last Updated: January 17, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SP2086

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Clinical Trials for SP2086

Trial ID Title Status Sponsor Phase Summary
NCT01969318 Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes Completed Jiangsu HengRui Medicine Co., Ltd. Phase 2 SP2086 is a new dipeptidyl peptidase(DPP)-4 inhibitor. This study aims to evaluate the efficacy and safety of SP2086 in combination therapy with Metformin in patients with Type 2 Diabetes in Metformin monotherapy Who have Inadequate Glycemic Control
NCT01969357 A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes Completed Jiangsu HengRui Medicine Co., Ltd. Phase 2 SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to explore the effective dose range of SP2086 in Patients with type 2 diabetes.
NCT01970033 Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes Unknown status Jiangsu HengRui Medicine Co., Ltd. Phase 3 SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to evaluate the efficacy and safety of SP2086 as monotherapy in patients with Type 2 Diabetes Mellitus in Metformin monotherapy Who Have Inadequate Glycemic Control treated with diet and exercise for 3 months
NCT01970046 A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes Unknown status Jiangsu HengRui Medicine Co., Ltd. Phase 3 SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to evaluate the efficacy and safety of SP2086 in combination therapy with Metformin in patients with Type 2 Diabetes Mellitus in Metformin monotherapy Who Have Inadequate Glycemic Control
NCT02500485 The Drug-drug Interaction of SHR3824 and SP2086 Recruiting Jiangsu HengRui Medicine Co., Ltd. Phase 1 The purpose of the study is to investigate the potential interaction between multiple oral doses of SHR3824 and multiple oral doses of SP2086 in healthy adult volunteers.
NCT02813863 The Drug-drug Interaction of SP2086 and Metformin Completed Jiangsu HengRui Medicine Co., Ltd. Phase 1 This is an open single and self-control study,planning to recruit 24 cases of healthy male volunteers.In the study,subjects were given SP2086 and metformin,and collects blood samples before and after medcine.The purpose is to evaluate the drug interaction between SP2086 and Metformin.
NCT02815657 The Drug-drug Interaction of SP2086 and Valsartan Completed Jiangsu HengRui Medicine Co., Ltd. Phase 1 The purpose of the study is to investigate the potential interaction between SP2086 and Valsartan after multiple oral doses treatment in healthy adult volunteers.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for SP2086

Condition Name

Condition Name for
Intervention Trials
Type 2 Diabetes 15
Renal Insufficiency 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Diabetes Mellitus, Type 2 5
Diabetes Mellitus 5
Renal Insufficiency 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for SP2086

Trials by Country

Trials by Country for
Location Trials
China 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for SP2086

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 2
Phase 2 2
Phase 1 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 8
Recruiting 5
Unknown status 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for SP2086

Sponsor Name

Sponsor Name for
Sponsor Trials
Jiangsu HengRui Medicine Co., Ltd. 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Johnson and Johnson
Express Scripts
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.